Investigational drug · Phase 2
SYL1801
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "SYL1801"
First trial start
2022
Nov 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYL1801", any sponsor or status.
Conditions studied
As listed on its trial records.
- Wet Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYL1801" as an intervention, largest first.
Sylentis, S.A.Industry
NCT05637255 · 99 participants · Start Nov 22, 2022 · Primary completion Dec 19, 2024
Drug: SYL1801 · For: Wet Macular Degeneration; Neovascular Age-related Macular Degeneration; Macular Degeneration
Sites: Brno, Czechia; Chomutov, Czechia; Frýdek-Místek, Czechia · 16 sites in all
Sylentis, S.A.Industry
NCT04782271 · 36 participants · Start Mar 17, 2021 · Primary completion Dec 21, 2021
Drug: SYL18001 sodium Low dose q.d; SYL18001 sodium Middle dose q.d and 2 more · For: Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers; Choroidal Neovascularization
Sites: Madrid, Spain
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Wet Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.